Item 2.02 Results of Operations and Financial Condition.

On January 19, 2022, RVL Pharmaceuticals plc (the "Company") issued a press release in connection with its investor day, which includes certain preliminary financial results for the quarter ended December 31, 2021. A copy of the press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K.

The information contained in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.





Item 9.01 Exhibits




(d) Exhibits.



Exhibit
No.        Description
  99.1       Press Release, dated January 19, 2022
104        Cover Page Interactive Data File (formatted as Inline XBRL)

© Edgar Online, source Glimpses